News

Amgen raised its 2026 outlook as broad product growth funds a deeper late-stage pipeline push amid biosimilar pressure on older franchises.

The biotech raised its full-year revenue forecast to $38.2 billion–$39.4 billion after second-quarter revenue rose 10% to $10.1 billion

How Amgen’s latest earnings event sets the stage for investors Amgen (AMGN) just released its second quarter 2026 results, reporting revenue of US$10.05b and net income of US$2.38b, alongside updated full year guidance that gives investors fresh numbers to work with. For the first half of 2026, Amgen reported revenue of US$18.67b and net income of US$4.19b. Basic earnings per share from continuing operations were US$7.77, with diluted EPS at US$7.71 for the period. The company now expects...

Amgen Inc (AMGN) delivers 10% revenue growth driven by key products like Repatha and UPLIZNA, while raising full-year 2026 guidance.

While the top- and bottom-line numbers for Amgen (AMGN) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Amgen (NASDAQ:AMGN) reported second-quarter revenue above $10 billion, up 10% from a year earlier, as growth across several key medicines offset competitive pressure on its bone-health franchise. The company raised its full-year revenue and adjusted earnings outlook while continuing to increase spen

Amgen (AMGN) delivered earnings and revenue surprises of +12.32% and +6.52%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

US equities rallied intraday, fueled by upbeat earnings reports and hopes that the Strait of Hormuz

US equity futures were tracking in the green on Tuesday as traders await the latest batch of corpora

Wall Street futures pointed moderately higher pre-bell Tuesday after software giant Palantir Technol

Today Earnings (a.m.): Merck, Pfizer, McDonald's, Caterpillar, Spotify, Apollo, TPG, Marathon Petroleum, Archer-Daniels-Midland, DuPont, Kimberly-Clark Earnings (p.m.): SpaceX, Advanced Micro Devices, ...

Biotech company Amgen (NASDAQ:AMGN) will be reporting earnings this Tuesday afternoon. Here’s what you need to know.

Amgen heads into Q2 earnings with a history of beats as investors watch key drug sales trends and seek updates on its MariTide obesity candidate.

Besides Wall Street's top-and-bottom-line estimates for Amgen (AMGN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2026.

EyePoint (EYPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biogen’s growth portfolio, which includes one closely watched Alzheimer’s drug, is a bright spot in the second quarter.

Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amgen is set to report Q2 earnings next month, with analysts expecting a single digit EPS decline.

Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Amgen trades at $365.22 per share and has stayed right on track with the overall market, gaining 12% over the last six months. At the same time, the S&P 500 has returned 7.7%.

Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

We recently compiled a list of the 10 Popular Penny Stocks on Robinhood to Watch in 2026. TScan Therapeutics, Inc. (NASDAQ:TCRX) is one of the most popular penny stocks. TheFly reported on May 6 that TCRX announced its first-quarter 2026 financial results, covering the period ended March 31, 2026, along with a corporate update. The […]

The latest fair value estimate for Amgen has shifted slightly, from US$350.03 to US$349.66, keeping modeled upside closely aligned with prior assumptions. That small adjustment fits with recent analyst commentary, where higher and lower price targets have been clustering around the current trading range as views on growth and execution remain mixed. As you read on, you will see how to track these changing signals and what they might mean for following Amgen’s evolving story over time. Stay...